4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Taysha Gene Therapies, Inc. (TSHA) operates in the Biotechnology industry and is headquartered in Dallas, United States with about 99 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TSHA reported $10M in revenue and ($109M) in net income.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Interactive charts & full statements → Open the TSHA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $10M | $8M | $16M | $2M |
| Operating Income (EBIT) | ($110M) | ($87M) | ($71M) | ($126M) |
| Net Income | ($109M) | ($89M) | ($112M) | ($166M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $6M | $0M | $2M | $2M | — |
| Operating Income (EBIT) | ($44M) | ($28M) | ($34M) | ($27M) | ($21M) | — |
| Net Income | ($42M) | ($28M) | ($33M) | ($27M) | ($22M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $343M | $160M | $173M | $126M | — |
| Total Liabilities | $96M | $89M | $98M | $125M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TSHA viewer.
About TickerBase · Data methodology & sources